Ascendis Pharma A/S (NASDAQ:ASND) Given New $174.00 Price Target at JPMorgan Chase & Co.

Ascendis Pharma A/S (NASDAQ:ASND) had its price target dropped by equities researchers at JPMorgan Chase & Co. from $180.00 to $174.00 in a research report issued on Wednesday, Benzinga reports. The brokerage currently has an “overweight” rating on the biotechnology company’s stock. JPMorgan Chase & Co.‘s price objective would indicate a potential upside of 34.81% from the company’s current price.

Other analysts have also issued research reports about the company. Evercore ISI increased their price objective on Ascendis Pharma A/S from $191.00 to $205.00 and gave the company an “outperform” rating in a research note on Tuesday, September 17th. Citigroup raised their price target on shares of Ascendis Pharma A/S from $178.00 to $207.00 and gave the stock a “buy” rating in a report on Tuesday, September 17th. StockNews.com raised shares of Ascendis Pharma A/S from a “sell” rating to a “hold” rating in a research note on Thursday, September 5th. Jefferies Financial Group raised their target price on Ascendis Pharma A/S from $174.00 to $196.00 and gave the stock a “buy” rating in a research note on Tuesday, August 13th. Finally, The Goldman Sachs Group upped their price target on Ascendis Pharma A/S from $180.00 to $200.00 and gave the company a “buy” rating in a research report on Tuesday, September 17th. Two analysts have rated the stock with a hold rating and twelve have given a buy rating to the company’s stock. According to MarketBeat.com, Ascendis Pharma A/S currently has a consensus rating of “Moderate Buy” and an average target price of $195.92.

Ascendis Pharma A/S Stock Up 0.3 %

Ascendis Pharma A/S stock opened at $129.07 on Wednesday. The firm has a fifty day simple moving average of $135.33 and a two-hundred day simple moving average of $134.73. Ascendis Pharma A/S has a twelve month low of $85.29 and a twelve month high of $161.00. The company has a market capitalization of $7.52 billion, a PE ratio of -13.43 and a beta of 0.64.

Ascendis Pharma A/S (NASDAQ:ASND) last released its earnings results on Tuesday, September 3rd. The biotechnology company reported ($2.05) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.54) by ($0.51). The firm had revenue of $38.75 million during the quarter, compared to the consensus estimate of $94.74 million. As a group, equities analysts expect that Ascendis Pharma A/S will post -7.2 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the business. Avoro Capital Advisors LLC increased its stake in shares of Ascendis Pharma A/S by 5.8% during the second quarter. Avoro Capital Advisors LLC now owns 4,196,661 shares of the biotechnology company’s stock valued at $572,341,000 after purchasing an additional 229,995 shares in the last quarter. Westfield Capital Management Co. LP raised its stake in Ascendis Pharma A/S by 1.1% during the first quarter. Westfield Capital Management Co. LP now owns 4,075,214 shares of the biotechnology company’s stock valued at $616,050,000 after buying an additional 44,580 shares during the last quarter. Capital International Investors boosted its holdings in Ascendis Pharma A/S by 0.5% in the first quarter. Capital International Investors now owns 2,191,312 shares of the biotechnology company’s stock worth $331,261,000 after acquiring an additional 10,044 shares in the last quarter. Price T Rowe Associates Inc. MD grew its stake in shares of Ascendis Pharma A/S by 23.3% in the first quarter. Price T Rowe Associates Inc. MD now owns 1,781,926 shares of the biotechnology company’s stock worth $269,374,000 after acquiring an additional 336,976 shares during the last quarter. Finally, Massachusetts Financial Services Co. MA increased its holdings in shares of Ascendis Pharma A/S by 5.8% during the second quarter. Massachusetts Financial Services Co. MA now owns 1,711,015 shares of the biotechnology company’s stock valued at $233,348,000 after acquiring an additional 93,185 shares in the last quarter.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.